Left ventricular hypertrophy regression with antihypertensive treatment: focus on Candesartan.
Cuspidi
Cesare
C
From Istituto di Medicina Cardiovascolare and Centro Interuniversitario di Fisiologia Clinica e Ipertensione, Università and Ospedale Maggiore IRCCS and Istituto Auxologico, Ospedale S Luca, Milano, Italy. dhipertensione@libero.it
Leonetti
Gastone
G
Zanchetti
Alberto
A
D000804:Angiotensin II / Q000037:antagonists & inhibitors; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use; D001713:Biphenyl Compounds; D004562:Electrocardiography; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D012084:Renin-Angiotensin System / Q000502:physiology; D013777:Tetrazoles / Q000627:therapeutic use; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; D000804:Angiotensin II; C081643:candesartan